



ELSEVIER

Contents lists available at ScienceDirect

International Journal of Infectious Diseases

journal homepage: www.elsevier.com/locate/ijid



Corrigendum

Corrigendum to “Cost-effectiveness of introducing a domestic pneumococcal conjugate vaccine (PCV7-TT) into the Cuban national immunization programme” [Int. J. Infect. Dis. 97 (2020) 182–189]

Anai García Fariñas^{a,*}, Nivaldo Linares-Pérez^a, Andrew Clark^b,
María Eugenia Toledo-Romaní^c, Nathalie El Omeiri^d, Martha C. Marrero Araújo^e,
Isabel Pilar González Luis^a, Gilda Toraño Peraza^c, Alicia Reyes Jiménez^c,
Lena López Ambrón^f, The Cuban Pneumococcal Vaccine Working Group

^a Finlay Vaccine Institute, Havana, Cuba

^b London School of Hygiene & Tropical Medicine, London, United Kingdom

^c Institute of Tropical Medicine Pedro Kouri, Havana, Cuba

^d Pan American Health Organization, Washington, D.C., USA

^e National School of Public Health, Havana, Cuba

^f Ministry of Public Health, Havana, Cuba

The authors regret that the Methods section has error in the formula. Corrections follow.

In the Modelling approach section . . .

For a given week (w) of age, the number of disease events D_w was calculated as:

$$D_w = P \times S \times A_w \times (1 - V_w)$$

where: $P \times S \times A_w$ is the number of disease events in week w of age; V_w is the effect of vaccination in week w of age; P is the number of person-years lived between birth and age 5.0 years in the birth cohort evaluated; S is the streptococcus pneumoniae (pneumococcal) disease event rate per 100,000 per year among children younger than 5 years before the introduction of vaccination; and A_w is the proportion of pneumococcal disease events in children younger than 5 years in week w of age.

In the Pneumococcal disease burden inputs section . . .

For each birth cohort, estimates of person-years lived between birth and age 5.0 years (P) were based on United Nations demographic projections (<https://population.un.org/wpp/>). We estimated disease event rates (S) separately for pneumococcal acute otitis media (AOM), non-severe pneumococcal pneumonia, severe pneumococcal pneumonia, pneumococcal meningitis and other non-pneumonia/non-meningitis pneumococcal disease (NPNM) (Table 1).

The authors would like to apologise for any inconvenience caused.

DOI of original article: <http://dx.doi.org/10.1016/j.ijid.2020.05.078>

* Corresponding author.

E-mail address: agfarinas@finlay.edu.cu (A.G. Fariñas).

<http://dx.doi.org/10.1016/j.ijid.2020.08.072>

1201-9712/© 2020 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Please cite this article in press as: A.G. Fariñas, et al., Corrigendum to “Cost-effectiveness of introducing a domestic pneumococcal conjugate vaccine (PCV7-TT) into the Cuban national immunization programme” [Int. J. Infect. Dis. 97 (2020) 182–189], Int J Infect Dis (2020), <https://doi.org/10.1016/j.ijid.2020.08.072>